Work

Clinical Significance of Pharmacogenetic Profiling in Akathisia Associated With Obsessive-Compulsive Disorder

Year: 2026
Type: article
Study design: Case Report
Abstract: Obsessive-compulsive disorder (OCD) involves involuntary, distressing thoughts and compulsive behaviors. While selective serotonin reuptake inhibitors (SSRIs) are widely used in the treatment of OCD, when administered concomitantly with antipsychotics, they can contribute to akathisia. Drug metabolism and side-effect profiles can be influenced by genetic variations in genes encoding cytochrome P450 (CYP450) enzymes. In this case report, the pharmacogenetic findings and clinical features of a 29-year-old male patient diagnosed with OCD and experiencing akathisia were evaluated. The patient received standard pharmacotherapy prior to the genetic test. However, pharmacogenetic analysis revealed that the patient was an intermediate metabolizer (IM) for CYP2D6, a normal (extensive) metabolizer for other CYP enzymes, and showed increased induction for CYP1A2. Despite beta-blocker therapy, akathisia persisted and subsided following the readjustment of the quetiapine dose. However, the simultaneous use of multiple psychotropic drugs, dose changes, and potential drug-drug interactions limited the interpretation of the pharmacogenetic findings. This case report highlights the potential role of pharmacogenetic tests in clinical practice, but demonstrates that they do not definitively predict treatment response or adverse effects. Larger studies are needed to determine the clinical utility of pharmacogenetic testing in the management of OCD.
Source: Cureus
Language: English
Subfield: Pharmacology
Open Access status: diamond
OpenAlex ID: W7235746227
FWCI:
Cites: 19
Cited by:
Related to: 10